JP2010508834A - 炭水化物に対する細胞性免疫を活性化し得る微生物またはその部分 - Google Patents

炭水化物に対する細胞性免疫を活性化し得る微生物またはその部分 Download PDF

Info

Publication number
JP2010508834A
JP2010508834A JP2009535633A JP2009535633A JP2010508834A JP 2010508834 A JP2010508834 A JP 2010508834A JP 2009535633 A JP2009535633 A JP 2009535633A JP 2009535633 A JP2009535633 A JP 2009535633A JP 2010508834 A JP2010508834 A JP 2010508834A
Authority
JP
Japan
Prior art keywords
core
positive
cells
immune response
microorganism
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2009535633A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010508834A5 (enExample
Inventor
シュテファン ゴレツ，
フィリップ ウルセメール，
アニャ ロフラー，
Original Assignee
グリコトープ ゲーエムベーハー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39200183&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP2010508834(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by グリコトープ ゲーエムベーハー filed Critical グリコトープ ゲーエムベーハー
Publication of JP2010508834A publication Critical patent/JP2010508834A/ja
Publication of JP2010508834A5 publication Critical patent/JP2010508834A5/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56972—White blood cells
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/40—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum bacterial
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/19—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/428—Undefined tumor antigens, e.g. tumor lysate or antigens targeted by cells isolated from tumor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • C07K16/3092—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated mucins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5058—Neurological cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5152—Tumor cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/521—Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/185—Escherichia
    • C12R2001/19—Escherichia coli
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2400/00—Assays, e.g. immunoassays or enzyme assays, involving carbohydrates
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2469/00—Immunoassays for the detection of microorganisms
    • G01N2469/20—Detection of antibodies in sample from host which are directed against antigens from microorganisms
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Food Science & Technology (AREA)
  • Wood Science & Technology (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Mycology (AREA)
  • Diabetes (AREA)
  • General Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Nutrition Science (AREA)
JP2009535633A 2006-11-10 2007-11-12 炭水化物に対する細胞性免疫を活性化し得る微生物またはその部分 Withdrawn JP2010508834A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP06090209A EP1920782A1 (en) 2006-11-10 2006-11-10 Carboyhdrate specific cellular immunity inducing microorganisms and fractions thereof
EP06090208.7A EP1920781B1 (en) 2006-11-10 2006-11-10 Compositions comprising a core-1 positive microorganism and their use for the treatment or prophylaxis of tumors
PCT/EP2007/009766 WO2008055703A2 (en) 2006-11-10 2007-11-12 Microorganisms or fractions thereof capable of activating cellular immunity against carbohydrates

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015075105A Division JP2015134813A (ja) 2006-11-10 2015-04-01 炭水化物に対する細胞性免疫を活性化し得る微生物またはその部分

Publications (2)

Publication Number Publication Date
JP2010508834A true JP2010508834A (ja) 2010-03-25
JP2010508834A5 JP2010508834A5 (enExample) 2011-01-06

Family

ID=39200183

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2009535633A Withdrawn JP2010508834A (ja) 2006-11-10 2007-11-12 炭水化物に対する細胞性免疫を活性化し得る微生物またはその部分
JP2009535632A Expired - Fee Related JP5771355B2 (ja) 2006-11-10 2007-11-12 微生物およびその部分が誘導する炭水化物特異的細胞性免疫
JP2015075105A Withdrawn JP2015134813A (ja) 2006-11-10 2015-04-01 炭水化物に対する細胞性免疫を活性化し得る微生物またはその部分
JP2015074801A Withdrawn JP2015133979A (ja) 2006-11-10 2015-04-01 微生物およびその部分が誘導する炭水化物特異的細胞性免疫

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2009535632A Expired - Fee Related JP5771355B2 (ja) 2006-11-10 2007-11-12 微生物およびその部分が誘導する炭水化物特異的細胞性免疫
JP2015075105A Withdrawn JP2015134813A (ja) 2006-11-10 2015-04-01 炭水化物に対する細胞性免疫を活性化し得る微生物またはその部分
JP2015074801A Withdrawn JP2015133979A (ja) 2006-11-10 2015-04-01 微生物およびその部分が誘導する炭水化物特異的細胞性免疫

Country Status (17)

Country Link
US (2) US9494587B2 (enExample)
EP (4) EP1920781B1 (enExample)
JP (4) JP2010508834A (enExample)
KR (2) KR20150054014A (enExample)
CN (1) CN101573138B (enExample)
AU (2) AU2007316819B2 (enExample)
BR (2) BRPI0718796A2 (enExample)
CA (2) CA2668603A1 (enExample)
EA (1) EA025395B1 (enExample)
ES (1) ES2715045T3 (enExample)
IL (2) IL198567A0 (enExample)
MX (1) MX2009005004A (enExample)
NO (1) NO20091748L (enExample)
NZ (1) NZ577559A (enExample)
PL (1) PL1920781T3 (enExample)
RU (1) RU2460074C2 (enExample)
WO (2) WO2008055703A2 (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014524260A (ja) * 2011-08-22 2014-09-22 グリコトープ ゲーエムベーハー Ｂａｃｔｅｒｏｉｄｅｓｘｙｌａｎｉｓｏｌｖｅｎｓ種の微生物
JP2014529403A (ja) * 2011-08-22 2014-11-13 グリコトープゲーエムベーハー 腫瘍抗原を保有する微生物
JP2015526711A (ja) * 2012-06-26 2015-09-10 セントル ホスピタリエ リージョナル ユニヴェルシテール ドゥ リールＣｅｎｔｒｅ Ｈｏｓｐｉｔａｌｉｅｒ Ｒｅｇｉｏｎａｌ Ｕｎｉｖｅｒｓｉｔａｉｒｅ ｄｅ Ｌｉｌｌｅ Ｍａｌｄｉ−ｔｏｆ質量分析による侵襲性真菌感染症の体外診断法

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20150307T1 (hr) 2006-09-10 2015-04-24 Glycotope Gmbh Upotreba ljudskih stanica podrijetlom iz ljudske leukemije za eksprimiranje protutijela
EP1920781B1 (en) * 2006-11-10 2015-03-04 Glycotope GmbH Compositions comprising a core-1 positive microorganism and their use for the treatment or prophylaxis of tumors
EP2119365B1 (de) 2008-05-13 2017-08-16 Glycotope GmbH Fermentationsprozess
AR071787A1 (es) * 2008-05-13 2010-07-14 Glycotope Gmbh Procedimiento de fermentacion, alimento fermentado producido por dicho procedimiento y auxiliar de procesamiento
AU2010281507A1 (en) * 2009-07-27 2012-03-01 The University Of North Carolina At Chapel Hill Enterococcus and fecal Bacteroides for rapid water quality assessment
GB2475226A (en) 2009-11-03 2011-05-18 Genetic Analysis As Universal Prokaryote 16S ribosome PCR primer pair
WO2011153226A2 (en) * 2010-06-01 2011-12-08 Moore Research Enterprises Llc Cellular constituents from bacteroides, compositions thereof, and therapeutic methods employing bacteroides or cellular constituents thereof
US20130259899A1 (en) * 2010-10-04 2013-10-03 Allen-Vercoe, Emma Molecular And Cellular Biology University Of Guelph Detection of fusobacterium in a gastrointestinal sample to diagnose gastrointestinal cancer
GB201112091D0 (en) 2011-07-14 2011-08-31 Gt Biolog Ltd Bacterial strains isolated from pigs
GB201117313D0 (en) 2011-10-07 2011-11-16 Gt Biolog Ltd Bacterium for use in medicine
CN102813916B (zh) * 2012-09-05 2015-03-11 北京希普生国际生物医学研究院 一种快速获取树突状细胞疫苗的制备方法及其应用
GB201306536D0 (en) 2013-04-10 2013-05-22 Gt Biolog Ltd Polypeptide and immune modulation
EP2818056A1 (en) * 2013-06-25 2014-12-31 Biosearch S.A. Probiotic bacteria comprising metals, metal nanoparticles and uses thereof
US11155801B2 (en) * 2013-08-06 2021-10-26 Trustees Of Dartmouth College Unglycosylated lysostaphin variant protein
SG11201607258SA (en) 2014-04-10 2016-10-28 Obi Pharma Inc Antibodies, pharmaceutical compositions and uses thereof
US9616114B1 (en) 2014-09-18 2017-04-11 David Gordon Bermudes Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity
CN104546933A (zh) * 2014-09-30 2015-04-29 深圳华大基因科技有限公司 粪拟杆菌在治疗或预防类风湿性关节炎或其相关疾病中的应用
CN104546932A (zh) * 2014-09-30 2015-04-29 深圳华大基因科技有限公司 卵形拟杆菌在治疗或预防类风湿性关节炎或其相关疾病中的应用
ES2658310T3 (es) 2014-12-23 2018-03-09 4D Pharma Research Limited Una cepa de bacteroides thetaiotaomicron y su uso en la reducción de la inflamación
EP3193901B1 (en) * 2014-12-23 2018-04-04 4D Pharma Research Limited Pirin polypeptide and immune modulation
US10076556B2 (en) * 2015-01-29 2018-09-18 Oxyrase, Inc. Methods for inhibiting tumor growth
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
PT3307288T (pt) 2015-06-15 2019-10-17 4D Pharma Res Ltd Composições compreendendo estirpes bacterianas
MA41060B1 (fr) 2015-06-15 2019-11-29 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
MA55434B1 (fr) 2015-06-15 2022-02-28 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
TWI759266B (zh) 2015-06-15 2022-04-01 英商4D製藥研究有限公司 包含細菌菌株之組合物之用途
MA41010B1 (fr) 2015-06-15 2020-01-31 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
MA45287A (fr) 2015-11-20 2018-08-22 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
GB201520497D0 (en) 2015-11-20 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
GB201520631D0 (en) 2015-11-23 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
GB201520638D0 (en) 2015-11-23 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
GB201612191D0 (en) 2016-07-13 2016-08-24 4D Pharma Plc Compositions comprising bacterial strains
PT3313423T (pt) 2016-03-04 2019-07-10 4D Pharma Plc Composições que compreendem a estirpe blautia bacteriana para tratar a hipersensibilidade visceral
AU2017290900A1 (en) * 2016-07-01 2019-01-17 Infinant Health, Inc Method for facilitating maturation of the mammalian immune system
TWI802545B (zh) 2016-07-13 2023-05-21 英商４Ｄ製藥有限公司 包含細菌菌株之組合物
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
GB201621123D0 (en) 2016-12-12 2017-01-25 4D Pharma Plc Compositions comprising bacterial strains
EP3378949A1 (en) * 2017-03-22 2018-09-26 Assistance Publique - Hôpitaux de Paris Method for determining the potential efficacy of anticancer treatment
RS61872B1 (sr) 2017-05-22 2021-06-30 4D Pharma Res Ltd Kompozicije koje sadrže bakterijske sojeve
WO2018215782A1 (en) 2017-05-24 2018-11-29 4D Pharma Research Limited Compositions comprising bacterial strain
JP6840272B2 (ja) 2017-06-14 2021-03-10 フォーディー ファーマ リサーチ リミテッド４Ｄ Ｐｈａｒｍａ Ｒｅｓｅａｒｃｈ Ｌｉｍｉｔｅｄ 細菌株を含む組成物
RS63393B1 (sr) 2017-06-14 2022-08-31 4D Pharma Res Ltd Kompozicije koje sadrže bakterijske sojeve
EP3638271B1 (en) 2017-06-14 2020-10-14 4D Pharma Research Limited Compositions comprising bacterial strains
MA51770A (fr) 2017-07-05 2020-05-13 Evelo Biosciences Inc Compositions et méthodes de traitement du cancer à l'aide de bifidobacterium animalis ssp. lactis
WO2019217951A1 (en) * 2018-05-11 2019-11-14 Obi Pharma Inc. Method for predicting human immune response
BR112020023373A2 (pt) 2018-05-18 2021-02-09 Daiichi Sankyo Company, Limited conjugado, composição, e, uso de um conjugado ou de uma composição
US12144834B2 (en) 2018-09-13 2024-11-19 Xbiome Inc. Methods and compositions for treating gastrointestinal and inflammatory disorders
EP4588511A3 (en) * 2019-07-18 2025-07-30 Theriva Biologics, Inc. Intestinal alkaline phosphatase-based treatments of metabolic disorders
EP4100742A4 (en) * 2020-02-03 2024-03-20 Technion Research & Development Foundation Limited Method for isolating a microorganism
CN115992084A (zh) * 2022-08-18 2023-04-21 吉林农业大学 表达牛巨噬细胞粒细胞集落刺激因子的重组乳酸菌及应用

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4166452A (en) 1976-05-03 1979-09-04 Generales Constantine D J Jr Apparatus for testing human responses to stimuli
US4256108A (en) 1977-04-07 1981-03-17 Alza Corporation Microporous-semipermeable laminated osmotic system
US4265874A (en) 1980-04-25 1981-05-05 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use
AU2353384A (en) 1983-01-19 1984-07-26 Genentech Inc. Amplification in eukaryotic host cells
US4672316A (en) 1983-08-19 1987-06-09 Werkzeugmaschinenfabrik Oerlikon-Buhrle Ag Method for calibrating a muzzle velocity measuring device
KR850004274A (ko) * 1983-12-13 1985-07-11 원본미기재 에리트로포이에틴의 제조방법
US4931275A (en) * 1985-12-02 1990-06-05 Yeda Research & Development Co., Ltd. Anti-tumor vaccines and their preparation
US5683674A (en) * 1987-01-07 1997-11-04 Imperial Cancer Research Technology Ltd. Antibody against human mucin core protein and method of preparing and using same
WO1990001335A1 (en) 1988-08-02 1990-02-22 Borody Thomas J Treatment of gastro-intestinal disorders
US5110911A (en) 1989-11-02 1992-05-05 Biomira, Inc. Human tumor-associated thomsen-friedenreich antigen
DE69233068T2 (de) 1991-02-27 2004-01-22 Micromet Ag Serin-reiche peptidlinker
JP3698370B2 (ja) 1992-04-13 2005-09-21 ダナ−ファーバー キャンサー インスティチュート インク 癌腫抗原用抗体
US5804187A (en) * 1992-11-16 1998-09-08 Cancer Research Fund Of Contra Costa Modified antibodies with human milk fat globule specificity
JP3626187B2 (ja) 1993-06-07 2005-03-02 バイカル インコーポレイテッド 遺伝子治療に適するプラスミド
DE4329004A1 (de) 1993-08-28 1995-03-09 Max Delbrueck Centrum Monoklonale Antikörper gegen das Thomsen-Friedenreich-Antigen, ihre Herstellung und ihre Verwendung zum Tumornachweis
US7137011B1 (en) * 1993-09-01 2006-11-14 Sandisk Corporation Removable mother/daughter peripheral card
US5997873A (en) * 1994-01-13 1999-12-07 Mount Sinai School Of Medicine Of The City University Of New York Method of preparation of heat shock protein 70-peptide complexes
US5961979A (en) 1994-03-16 1999-10-05 Mount Sinai School Of Medicine Of The City University Of New York Stress protein-peptide complexes as prophylactic and therapeutic vaccines against intracellular pathogens
US5772995A (en) * 1994-07-18 1998-06-30 Sidney Kimmel Cancer Center Compositions and methods for enhanced tumor cell immunity in vivo
JP2660175B2 (ja) * 1994-10-19 1997-10-08 北海道 キクイモ由来のレクチンおよびその分離精製法
US5739277A (en) 1995-04-14 1998-04-14 Genentech Inc. Altered polypeptides with increased half-life
AU723325B2 (en) 1995-06-23 2000-08-24 President And Fellows Of Harvard College Transcriptional regulation of genes encoding vascular endothelial growth factor receptors
KR100249442B1 (ko) * 1995-12-27 2000-05-01 시바타 마사하루 스트렙토코커스아갈락티아에ia형또는ib형표면다당을주성분으로하는암전이저해제
GB9603256D0 (en) 1996-02-16 1996-04-17 Wellcome Found Antibodies
EP0906444A1 (de) 1996-04-19 1999-04-07 Gabriele Pecher Gentransfizierte humane dendritische zellen, ihre herstellung und ihre verwendung, bevorzugt als vakzine
DE69815707T2 (de) * 1997-11-20 2004-07-01 Vical, Inc., San Diego Behandlung von krebs durch verwendung von zytokin-exprimierender polynukleotiden und zusammensetzungen dafür
US5948646A (en) 1997-12-11 1999-09-07 Fordham University Methods for preparation of vaccines against cancer comprising heat shock protein-peptide complexes
DE69939813D1 (de) * 1998-02-20 2008-12-11 Tanox Inc Inhibitoren der komplement-aktivierung
JP2000028599A (ja) * 1998-04-15 2000-01-28 Ebara Corp Ｄ―マンノ―ス識別アフィニティ―担体とその使用方法
CA2363297C (en) 1999-03-02 2011-08-09 Michael J. Betenbaugh Engineering intracellular sialylation pathways
WO2000058499A1 (fr) 1999-03-30 2000-10-05 Japan Tobacco Inc. Procede pour la production d'anticorps monoclonal
US7147850B2 (en) * 1999-08-18 2006-12-12 Altarex Medical Corp. Therapeutic binding agents against MUC-1 antigen and methods for their use
JP2003519096A (ja) 1999-08-18 2003-06-17 アルタレックス コーポレーション Ｍｕｃ−１抗原に対する治療用抗体およびその使用方法
US6984384B1 (en) * 1999-09-30 2006-01-10 Health Research, Inc. Stress protein compositions and methods for prevention and treatment of cancer and infectious disease
AUPQ899700A0 (en) 2000-07-25 2000-08-17 Borody, Thomas Julius Probiotic recolonisation therapy
US20030138769A1 (en) * 2000-08-16 2003-07-24 Birkett Ashley J. Immunogenic HBc chimer particles having enhanced stability
GB0029360D0 (en) 2000-12-01 2001-01-17 Univ Nottingham Humanised antibodies and uses thereof
WO2003003985A2 (en) * 2001-07-06 2003-01-16 Sloan-Kettering Institute For Cancer Research Polyvalent conjugate vaccine for cancer
DE10139428A1 (de) 2001-08-17 2003-03-27 Nemod Immuntherapie Ag Herstellung und Verwendung von humanen CD124 und CD116 positiven Tumorzelllinien zur Herstellung von allogenen oder semi-allogenen Immuntherapeutika
EP1419176A2 (en) 2001-08-17 2004-05-19 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Glycoconjugates of sialic acid derivates, methods for their production and use thereof
GB0125473D0 (en) 2001-10-24 2001-12-12 Syngenta Ltd Chemical process
CN1201817C (zh) * 2001-11-09 2005-05-18 北京大学肝病研究所 一种治疗肝癌的肿瘤ct抗原免疫诱导剂及其制备方法
WO2003044051A1 (en) 2001-11-20 2003-05-30 Atgen Co., Ltd. Novel peptides conferring environmental stress resistance and fusion proteins including said peptides
WO2004009632A2 (de) * 2002-07-22 2004-01-29 Nemod Immuntherapie Ag Verfahren zur herstellung eines immunstimulatorischen muzins (muc1)
DE60334382D1 (de) 2002-08-16 2010-11-11 Glycotope Gmbh Verfahren zur herstellung von temperaturinduzierten tumorzell-lysaten zur verwendung als immunogene verbindungen
WO2004029621A2 (en) * 2002-09-26 2004-04-08 Novartis Ag Tcell mediator/modulator assay based upon tcell restricted transgenic mouse
DE10256900A1 (de) 2002-11-29 2004-06-24 Nemod Immuntherapie Ag Tumorspezifische Erkennungsmoleküle
DK1604016T3 (da) * 2003-02-27 2009-05-18 Northwest Biotherapeutics Inc In vitro-fremgangsmåde til differentiering af monocytiske dendritiske precursorceller i umodne dendritiske celler
GB0315991D0 (en) * 2003-07-08 2003-08-13 Dakocytomation Denmark As Standard
WO2005019258A2 (en) 2003-08-11 2005-03-03 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
WO2005017130A2 (en) 2003-08-18 2005-02-24 Glycotope Gmbh Tumour cell lines nm-f9 (dsm acc2606) and nm-d4 (dsm acc2605), uses thereof
FR2861080B1 (fr) 2003-10-20 2006-02-17 Lab Francais Du Fractionnement Anticorps presentant un taux de fucose et de galactose optimise
US20050203010A1 (en) * 2003-11-14 2005-09-15 Atgen Co., Ltd. Novel peptides conferring environmental stress resistance and fusion proteins including said peptides
JP4913604B2 (ja) 2004-02-13 2012-04-11 グリコトープ ゲーエムベーハー 高活性糖タンパク質−製造条件、及びその効率的製造方法
BRPI0512921A (pt) * 2004-07-01 2008-04-22 Den Kgl Veterinaer Og Landboho processo para tratamento e profilaxia de ms
CA2582252C (en) * 2004-07-26 2014-08-26 The Research Foundation Of State University Of New York Therapeutic use of anti-tf-antigen antibody
WO2007016521A2 (en) * 2005-08-01 2007-02-08 Her Majesty In Right Of Canada As Represented By The Minister Of Agriculture And Agri-Foods Canada Low fiber yellow canola seeds comprising high oleic, low linolenic oil
HRP20150307T1 (hr) 2006-09-10 2015-04-24 Glycotope Gmbh Upotreba ljudskih stanica podrijetlom iz ljudske leukemije za eksprimiranje protutijela
EP1920781B1 (en) 2006-11-10 2015-03-04 Glycotope GmbH Compositions comprising a core-1 positive microorganism and their use for the treatment or prophylaxis of tumors
AR071787A1 (es) * 2008-05-13 2010-07-14 Glycotope Gmbh Procedimiento de fermentacion, alimento fermentado producido por dicho procedimiento y auxiliar de procesamiento
EP2281844A1 (en) * 2009-07-31 2011-02-09 Glycotope GmbH MUC 1 antibodies
BR112014004065A2 (pt) * 2011-08-22 2017-03-14 Glycotope Gmbh micro-organismos carregando um antígeno de tumor

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
JPN5009019425; ＣＬＡＵＳＥＮ　Ｈ: ＭＯＬＥＣＵＬＡＲ　ＩＭＭＵＮＯＬＯＧＹ Ｖ２５　Ｎ２, 1988, Ｐ１９９-２０４ *
JPN5010000862; ＧＯＬＥＴＺ　Ｓ: 'ＴＨＯＭＳＥＮ-ＦＲＩＥＤＥＮＲＥＩＣＨ　ＡＮＴＩＧＥＮ：ＴＨＥ　ＨＩＤＤＥＮ　ＴＵＭＯＲ　ＡＮＴＩＧＥＮ' ＡＤＶＡＮＣＥＳ　ＩＮ　ＥＸＰＥＲＩＭＥＮＴＡＬ　ＭＥＤＩＣＩＮＥ　ＡＮＤ　ＢＩＯＬＯＧＹ Ｖ５３５, 2003, Ｐ１４７-１６２ *
JPN6013003156; Ｂｒｉｔｉｓｈ　Ｊｏｕｒｎａｌ　ｏｆ　Ｈａｅｍａｔｏｌｏｇｙ Ｖｏｌ．４７, 1981, ｐ．４５３-４６０ *
JPN6013003158; Ｊ．　Ｍｏｌ．　Ｍｅｄ． Ｖｏｌ．７５, 1997, ｐ．５９４-６０２ *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014524260A (ja) * 2011-08-22 2014-09-22 グリコトープ ゲーエムベーハー Ｂａｃｔｅｒｏｉｄｅｓｘｙｌａｎｉｓｏｌｖｅｎｓ種の微生物
JP2014529403A (ja) * 2011-08-22 2014-11-13 グリコトープゲーエムベーハー 腫瘍抗原を保有する微生物
JP2015526711A (ja) * 2012-06-26 2015-09-10 セントル ホスピタリエ リージョナル ユニヴェルシテール ドゥ リールＣｅｎｔｒｅ Ｈｏｓｐｉｔａｌｉｅｒ Ｒｅｇｉｏｎａｌ Ｕｎｉｖｅｒｓｉｔａｉｒｅ ｄｅ Ｌｉｌｌｅ Ｍａｌｄｉ−ｔｏｆ質量分析による侵襲性真菌感染症の体外診断法

Also Published As

Publication number Publication date
US9494587B2 (en) 2016-11-15
US20100303837A1 (en) 2010-12-02
WO2008055703A3 (en) 2008-12-04
AU2007316820B2 (en) 2013-09-05
MX2009005004A (es) 2009-07-31
EP2099480B1 (en) 2019-01-09
HK1136219A1 (en) 2010-06-25
IL198626A (en) 2015-05-31
RU2460074C2 (ru) 2012-08-27
IL198567A0 (en) 2011-08-01
EP1920781B1 (en) 2015-03-04
IL198626A0 (en) 2011-08-01
AU2007316819A1 (en) 2008-05-15
RU2009122204A (ru) 2010-12-20
AU2007316819B2 (en) 2013-08-22
NO20091748L (no) 2009-07-14
EP1920781A1 (en) 2008-05-14
AU2007316820A1 (en) 2008-05-15
CA2668704A1 (en) 2008-05-15
WO2008055703A2 (en) 2008-05-15
WO2008055702A1 (en) 2008-05-15
EP1920782A1 (en) 2008-05-14
EP2099480B2 (en) 2024-06-12
JP2015134813A (ja) 2015-07-27
EP2099480A2 (en) 2009-09-16
KR20150054014A (ko) 2015-05-19
BRPI0718796A2 (pt) 2014-02-18
EP2101814A1 (en) 2009-09-23
US20100158952A1 (en) 2010-06-24
JP2015133979A (ja) 2015-07-27
PL1920781T3 (pl) 2015-06-30
ES2715045T3 (es) 2019-05-31
EA025395B1 (ru) 2016-12-30
JP2010508833A (ja) 2010-03-25
US8592165B2 (en) 2013-11-26
JP5771355B2 (ja) 2015-08-26
CN101573138A (zh) 2009-11-04
EA200970471A1 (ru) 2009-12-30
BRPI0719005A2 (pt) 2013-12-17
WO2008055703A9 (en) 2008-10-02
CA2668603A1 (en) 2008-05-15
KR20090080554A (ko) 2009-07-24
NZ577559A (en) 2012-01-12
CN101573138B (zh) 2015-04-29

Similar Documents

Publication Publication Date Title
JP5771355B2 (ja) 微生物およびその部分が誘導する炭水化物特異的細胞性免疫
CN105229142B (zh) 免疫刺激剂
CN101600454A (zh) 诱导碳水化合物特异性细胞免疫性的微生物及其片段
JP6148671B2 (ja) 腫瘍抗原を保有する微生物
TW201934138A (zh) 用於治療或預防癌症之組合療法
TW201938179A (zh) 用於治療或預防癌症之組合療法
HK1136219B (en) Microorganisms or fractions thereof capable of activating cellular immunity against carbohydrates
HUE025289T2 (en) Preparations containing a CORE-1 positive microorganism and their use for treating or preventing tumors
van Sorge et al. N-GLYCOSYLATION OF CAMPYLOBACTER JEJUNI PROTEINS INHIBITS DENDRITIC CELL RESPONSES THROUGH THE C-TYPE LECTIN MGL

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20101111

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20101111

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20111031

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130125

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130425

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20130425

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140107

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140324

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140331

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140507

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20140507

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20141201

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150401

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20150413

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20150416